Research update · 1 October 2026. New Phase 3 results for investigational retatrutide were published on 29 September 2026. This page summarizes the research status and links the new evidence to Avelqor’s existing documentation resources. It does not provide treatment or dosing guidance.
What changed in September 2026?
Phase 3 results from the TRIUMPH program have now been reported in peer-reviewed and sponsor sources. Retatrutide remains an investigational GIP, GLP-1 and glucagon receptor agonist and is not an approved medicine.
TRIUMPH-1
The Phase 3 TRIUMPH-1 trial enrolled adults with obesity without diabetes and compared once-weekly retatrutide with placebo over 80 weeks. The peer-reviewed report was published in the New England Journal of Medicine on 29 September 2026.
Read the peer-reviewed TRIUMPH-1 publication →
TRIUMPH-2
TRIUMPH-2 evaluated retatrutide in adults with type 2 diabetes and obesity or overweight. Eli Lilly reported that the highest-dose group had an average body-weight change of 20.8% over 80 weeks and an average A1C reduction of up to 1.6 percentage points. These are clinical-trial results for Lilly’s investigational drug and should not be transferred to commercial research-material products.
Read Lilly’s TRIUMPH-2 results →
Why clinical evidence and commercial batch evidence are different
A clinical publication can establish what was observed with the investigational material used in that trial. It does not verify the identity, purity, measured content or suitability of a separately supplied commercial research-material lot. Those questions require lot-specific analytical documentation.
Retatrutide documentation at Avelqor Labs
Retatrutide Research Documentation Guide · Retatrutide 10 mg product record · COA & Batch Verification · Batch Documentation Index · Quality & Testing
Research FAQ
Is retatrutide approved?
No. As of 1 October 2026, retatrutide remains investigational and has not been approved by a regulatory agency.
Do the Phase 3 results verify an Avelqor research vial?
No. Clinical evidence and commercial batch verification are separate. A supplied lot requires its own traceable analytical documentation.
Where can the current research evidence be checked?
Use the linked peer-reviewed publication, sponsor trial information and Avelqor’s Research Library. For commercial material verification, use the Batch Documentation Index and COA & Batch Verification pages.
Research use only. Avelqor Labs does not provide medical advice, dosing, injection, treatment or self-administration guidance. Research materials are not intended for human or veterinary use, consumption or administration.